Inactive Instrument

Clementia Pharmaceuticals Inc Stock price

Equities

CA1855751071

Biotechnology & Medical Research

Dynamic Chart
Managers TitleAgeSince
Chief Tech/Sci/R&D Officer 64 -
Corporate Officer/Principal 57 13-10-31
Members of the board TitleAgeSince
Director/Board Member 69 13-05-31
More insiders
Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models. It is developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO). Its programs focus on diseases involving tissue transformation via retinoic acid receptors (RARs). The Company also has an eye drop formulation of palovarotene that can potently increase tear production and decrease corneal damage.
More about the company
  1. Stock
  2. Equities
  3. Stock Clementia Pharmaceuticals Inc - Nasdaq